NASDAQ
No price data available for this timeframe.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Open
$7.75
Previous Close
$10.20
Day High
$10.20
Day Low
$7.00
52 Week High
$16.10
52 Week Low
$2.00